PWM
NVO

Proathlete Wealth Management’s Novo Nordisk NVO Stock Holding History

Proathlete Wealth Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06K Buy
43
+8
+23% +$344 ﹤0.01% 216
2026
Q1 		$1.29K Buy
35
+7
+25% +$332 ﹤0.01% 243
2025
Q4 		$1.42K Buy
28
+5
+22% +$256 ﹤0.01% 256
2025
Q3 		$1.28K Sell
23
-8
-26% -$468 ﹤0.01% 190
2025
Q2 		$2.14K Buy
31
+27
+675% +$1.84K ﹤0.01% 199
2025
Q1 		$277 Buy
+4
New +$330 ﹤0.01% 187

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Proathlete Wealth Management's NVO Position: Q2 2026 in Review

Proathlete Wealth Management increased its Novo Nordisk (NVO) stake by 23% in Q2 2026, buying an estimated $344 and bringing the position to 43 shares worth $2.06K. The position accounts for ﹤0.01% of the portfolio, ranked #216.

Proathlete Wealth Management first reported a position in NVO in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.14K in Q2 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Proathlete Wealth Management held 43 shares of Novo Nordisk worth $2.06K as of Q2 2026.
  • Proathlete Wealth Management bought 8 Novo Nordisk shares in Q2 2026, an estimated $344.
  • Novo Nordisk made up ﹤0.01% of Proathlete Wealth Management's portfolio in Q2 2026, its #216 holding.
  • Proathlete Wealth Management first reported a position in Novo Nordisk in Q1 2025 and has held it in 6 quarters since.
  • Proathlete Wealth Management's Novo Nordisk position peaked at $2.14K in Q2 2025.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Proathlete Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.